Finally, the combination of FF and UME caused a greater reduction in ACh and ChAT levels in sensitised AECs compared to normal cells, suggesting a potential additional pharmacological interaction between corticosteroids and mAChRs antagonists, which supports the rationale for the use of ICS/LAMA as a treatment approach for subjects with asthma and strengthens the pharmacological rationale for adding a LAMA to the established use of a combination of long-acting b-agonist/ICS in the context of “triple therapy”. The gene discussed is CHAT; the disease is asthma.